

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. SBL-001US		SERIAL NO. 09/892,613	
				APPLICANT Shawn Shui-on LEUNG			
				FILING DATE June 27, 2001		GROUP 1643	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
/DB/	5,789,554	08/04/98	Leung et al.	---	---		
↓	5,859,205	01/12/99	Adair et al.	---	---		
↓	6,187,287	02/13/01	Leung et al.	---	---		
/DB/	6,632,927	10/14/03	Adair et al.	---	---		
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
/DB/	Hamilton, Anita et al., "A Humanized Antibody against Human Cytomegalovirus (CMV) gpUL75 (gH) for Prophylaxis or Treatment of CMV Infections", Journal of Infectious Diseases, vol. 176:59-68 (1997)						
↓	Leung, Shui-on et al., "Construction and Characterization of a Humanized, Internalizing, B-Cell (CD-22) Specific Leukemia/Lymphoma Antibody, LL2", Molecular Immunology, vol. 32(17/18): 1413-1427 (1995)						
↓	Reichmann, Lutz et al., "Reshaping Human Antibodies for Therapy", Nature, vol. 332: 323-327 (March 1988)						
↓	Rosok, Mae Joanne et al., "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab", Journal of Biological Chemistry, vol. 271(37): 22611-22618 (September 1996)						
↓	Shan, Daming et al., "Characterization of scFV-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths", Journal of Immunology, vol. 162: 6589-6595 (1999)						
↓	Shearman, Clyde et al., "Construction, Expression, and Characterization of Humanized Antibodies Directed Against the Human α/β TCell Receptor", Journal of Immunology, vol. 147 (12): 4366-4373 (December 1991)						
↓	Wu, Tai Te, "From Esoteric Theory to Therapeutic Antibodies", Applied Biochem and Biotech, vol. 47: 107-118 (1994)						
/DB/	Zhengxing, Qu et al., "Humanization of Immu31, an α -Fetoprotein-specific Antibody", Clinical Cancer Research, vol. 5 (Suppl.):3095s-3100s (October 1999)						
EXAMINER /David Blanchard/				DATE CONSIDERED 08/28/2007			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.